Ceftobiprole: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Ceftobiprole": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 24: | Line 24: | ||
}} | }} | ||
}} | }} | ||
__NOTOC__ | |||
{{ | {{CMG}} | ||
==Overview== | |||
'''Ceftobiprole''' is an experimental [[cephalosporin]] [[antibiotic]] with activity against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']].<ref>{{cite journal |author=Yun HC, Ellis MW, Jorgensen JH |title=Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees |journal= |volume= |issue= |pages= |year=2007 |pmid=17911001 |doi=10.1016/j.diagmicrobio.2007.06.023}}</ref> It was discovered by [[Basilea Pharmaceutica]] and is being developed by [[Johnson & Johnson Pharmaceutical Research and Development]].<ref>[http://www.basilea.com/template_loader.php?tplpage_id=160 Basilea.com]</ref> | '''Ceftobiprole''' is an experimental [[cephalosporin]] [[antibiotic]] with activity against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']].<ref>{{cite journal |author=Yun HC, Ellis MW, Jorgensen JH |title=Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees |journal= |volume= |issue= |pages= |year=2007 |pmid=17911001 |doi=10.1016/j.diagmicrobio.2007.06.023}}</ref> It was discovered by [[Basilea Pharmaceutica]] and is being developed by [[Johnson & Johnson Pharmaceutical Research and Development]].<ref>[http://www.basilea.com/template_loader.php?tplpage_id=160 Basilea.com]</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | |||
[[Category:cephalosporin antibiotics]] | [[Category:cephalosporin antibiotics]] | ||
[[Category:Drug]] | |||
Latest revision as of 19:09, 4 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftobiprole is an experimental cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus.[1] It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development.[2]
References
- ↑ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.
- ↑ Basilea.com